Form 4: Denali Therapeutics Director David P. Schenkein Reports Beneficial Ownership Changes
SEC Form 4
Director David P. Schenkein reports acquisition of restricted stock units and stock options in Denali Therapeutics.
Summary
- On May 31, 2024, David P. Schenkein, a director of Denali Therapeutics Inc., reported changes in beneficial ownership.
- Schenkein acquired 5,967 shares of common stock represented by Restricted Stock Units (RSUs) at a price of $0.
- These RSUs vest upon the earlier of one year from the grant date or the day preceding the next annual meeting of stockholders.
- Schenkein also acquired 17,901 stock options with an exercise price of $18.56, vesting under the same conditions as the RSUs and expiring on May 31, 2034.
- Following these transactions, Schenkein directly owns 21,496 shares of common stock, including unvested RSUs.
- Additionally, 31,232 shares are held by the Amy P. Schenkein 2004 Revocable Trust, and 26,232 shares are held by the David P. Schenkein 2004 Revocable Trust.
- Schenkein also directly owns 17,901 derivative securities (stock options).
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director generally indicates confidence in the company's prospects, but it's a routine transaction.
Positives
- The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.
- The vesting schedule aligns the director's interests with the long-term success of the company.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and stock options suggests a focus on long-term performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the biotechnology industry. Monitoring such filings can provide insights into management's sentiment and alignment with shareholder interests.
Stakeholder Impact
- The transactions may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 05/31/2024 | Date of earliest transaction (acquisition of RSUs and stock options) |
| 05/31/2034 | Expiration date of the stock options |
| 06/04/2024 | Date of signature by power of attorney |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.